{
    "id": 2468,
    "fullName": "NOTCH1 act mut",
    "impact": "unknown",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "NOTCH1 act mut indicates that this variant results in a gain of function in the Notch1 protein. However the specific amino acid change has not been identified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 4851,
        "geneSymbol": "NOTCH1",
        "terms": [
            "NOTCH1",
            "AOS5",
            "AOVD1",
            "hN1",
            "TAN1"
        ]
    },
    "variant": "act mut",
    "createDate": "10/24/2014",
    "updateDate": "09/04/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 7154,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Brontictuzumab (OMP-52M51) inhibited tumor growth and reduced cancer stem cells in xenograft models of tumor derived from a breast cancer patient harboring activating NOTCH1 mutations (Cancer Res 2013;73(8 Suppl):Abstract nr 3728).",
            "molecularProfile": {
                "id": 2334,
                "profileName": "NOTCH1 act mut"
            },
            "therapy": {
                "id": 839,
                "therapyName": "Brontictuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6111,
                    "pubMedId": null,
                    "title": "Anti-Notch1 antibody (OMP-52M51) impedes tumor growth and cancer stem cell frequency (CSC) in a chemo-refractory breast cancer xenograft model with an activating Notch1 mutation and screening for activated Notch1 across multiple solid tumor types.",
                    "url": "http://cancerres.aacrjournals.org/content/73/8_Supplement/3728.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1263,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the gamma secretase inhibitor PF-03084014 reduced Notch1 cleavage, decreased activation of Notch targets, and increased apoptosis in colorectal cancer cell lines exhibiting increased Notch activation (PMID: 23868008).",
            "molecularProfile": {
                "id": 2334,
                "profileName": "NOTCH1 act mut"
            },
            "therapy": {
                "id": 859,
                "therapyName": "PF-03084014",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 978,
                    "pubMedId": 23868008,
                    "title": "Tumours with elevated levels of the Notch and Wnt pathways exhibit efficacy to PF-03084014, a \u03b3-secretase inhibitor, in a preclinical colorectal explant model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23868008"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7156,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, xenograft models of patient-derived acute lymphocytic leukemia cells harboring NOTCH1 activating muatations demonstrated better response to Brontictuzumab (OMP-52M51) compared to NOTCH1 wild-type models (PMID: 23774673).",
            "molecularProfile": {
                "id": 2334,
                "profileName": "NOTCH1 act mut"
            },
            "therapy": {
                "id": 839,
                "therapyName": "Brontictuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2506,
                    "pubMedId": 23774673,
                    "title": "Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23774673"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10054,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Kisqali (ribociclib) and Adexone (dexamethasone) resulted in reduced leukemia burden and a greater survival benefit in a NOTCH1 activated T-cell acute lymphoblastic leukemia patient derived xenograft (PDX) model when compared to control or either agent alone (PMID: 28151717).",
            "molecularProfile": {
                "id": 2334,
                "profileName": "NOTCH1 act mut"
            },
            "therapy": {
                "id": 5355,
                "therapyName": "Dexamethasone + Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 5602,
                "name": "T-cell adult acute lymphocytic leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7921,
                    "pubMedId": 28151717,
                    "title": "Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28151717"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2334,
            "profileName": "NOTCH1 act mut",
            "profileTreatmentApproaches": [
                {
                    "id": 13815,
                    "name": "NOTCH1 Inhibitor",
                    "profileName": "NOTCH1 act mut"
                },
                {
                    "id": 13813,
                    "name": "NOTCH Inhibitor (Pan)",
                    "profileName": "NOTCH1 act mut"
                },
                {
                    "id": 13816,
                    "name": "NOTCH1 Antibody",
                    "profileName": "NOTCH1 act mut"
                },
                {
                    "id": 13814,
                    "name": "Gamma secretase inhibitor",
                    "profileName": "NOTCH1 act mut"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}